Joana M Murad
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2019First federal award
$11.6MFederal grants as PI18 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
18 awards · $11.6M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jun 16, 2026 | NIH | SBIR Phase I Engineered Tregs as a therapy to Gaucher syndrome | $311K | CELDARA MEDICAL, LLC |
| Aug 5, 2025 | NIH | SBIR Phase II Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS) | $921K | CELDARA MEDICAL, LLC |
| Mar 11, 2025 | NIH | STTR Phase II A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome | $956K | CELDARA MEDICAL, LLC |
| Aug 30, 2024 | NIH | SBIR Phase II Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS) | $921K | CELDARA MEDICAL, LLC |
| Jul 31, 2024 | NIH | SBIR Phase II Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes | $1000K | CELDARA MEDICAL, LLC |
| Feb 22, 2024 | NIH | STTR Phase II A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome | $994K | CELDARA MEDICAL, LLC |
| Sep 8, 2023 | NIH | SBIR Phase II Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes | $999K | CELDARA MEDICAL, LLC |
| Aug 9, 2023 | NIH | SBIR Phase II Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas | $769K | CELDARA MEDICAL, LLC |
| Sep 22, 2022 | NIH | SBIR Phase II Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes | $300K | CELDARA MEDICAL, LLC |
| Sep 1, 2022 | NIH | SBIR Phase II Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas | $713K | CELDARA MEDICAL, LLC |
| Jul 25, 2022 | NIH | SBIR Phase I CAR T platform to treat solid tumors | $368K | CELDARA MEDICAL, LLC |
| Dec 9, 2021 | NIH | STTR Phase I A Novel Broad-spectrum Antiviral Agent | $291K | CELDARA MEDICAL, LLC |
| Sep 8, 2021 | NIH | SBIR Phase II Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas | $274K | CELDARA MEDICAL, LLC |
| Dec 31, 2020 | NIH | STTR Phase I A Novel Broad-spectrum Antiviral Agent | $300K | CELDARA MEDICAL, LLC |
| Aug 14, 2020 | NIH | SBIR Phase II Cellular Immunotherapy for Systemic Sclerosis | $731K | CELDARA MEDICAL, LLC |
| Dec 19, 2019 | NIH | SBIR Phase I A novel antibody therapy for Sin Nombre virus infection | $294K | CELDARA MEDICAL, LLC |
| Sep 16, 2019 | NIH | SBIR Phase II Complex 3-Dimensional in vitro Human Skin Tissue Models for Scleroderma | $738K | CELDARA MEDICAL, LLC |
| Aug 20, 2019 | NIH | SBIR Phase II Cellular Immunotherapy for Systemic Sclerosis | $750K | CELDARA MEDICAL, LLC |
Peer ranks
Federal funding#46
Awards as PI#24
Patents#273
Companies
- CELDARA MEDICAL, LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.